Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Recipient : Kindred Biosciences
Deal Size : Undisclosed
Deal Type : Divestment
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction
Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $43.0 million
March 16, 2020
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Recipient : Kindred Biosciences
Deal Size : Undisclosed
Deal Type : Divestment
LOOKING FOR A SUPPLIER?